Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug ...

Pfizer said its blood-cancer treatment met the main goal of an ongoing late-stage study, significantly extending the time patients lived without their disease worsening compared with a standard drug ...

Pfizer Inc. PFE on Wednesday shared topline results from the late-stage study of its cancer treatment, ELREXFIO (elranatamab) ...

(NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO ® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM ...

Pfizer (PFE) stock is in focus as a trial for the company's Elrexfio multiple myeloma drug hit the main goal with patients on ...

Pfizer announces positive results from phase 3 MagnetisMM-5 study of Elrexfio as monotherapy in adults with relapsed or refractory multiple myeloma: New York Thursday, April 30, 2 ...

Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic ...

Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or ...

About 90 percent of people fully inoculated by the Pfizer-BioNTech vaccine are well protected from variants of the novel ...

Pfizer Inc. (NYSE: PFE) disclosed the death of a participant in a long-term open-label extension study of marstacimab in patients with hemophilia A or B. In October 2024, the FDA approved Pfizer’s ...

New England Journal of Medicine lets Anthony Fauci and his onetime deputy play down results in editorial alongside study from ...